Bob’s Discount Furniture, Inc. ($BOBS) shares tumbling 6.8% in extended trading after Mixed Q4...

Staff Writer - March 17, 2026 4:50 pm

Bob's Discount Furniture, Inc. (NYSE: BOBS) shares are declining 6.83 percent in extended trading after Q4 2025 results. The company reported mixed results for the...

CATALYST News

Outlook Therapeutics ($OTLK) Secures FDA Approval for LYTENAVA™

NewsDesk - July 24, 2026 3:10 pm

Charter Communications ($CHTR) Beats Q2 EPS Estimates; Revenue Decline Driven by Lower Video Revenue

NewsDesk - July 24, 2026 8:21 am

SLB ($SLB) Q2 performance beats expectations; EBITDA and cash flow robust

Staff Writer - July 24, 2026 8:13 am

Sensient Technologies ($SXT) Beats Q2 EPS and Revenue Estimates; Projects Strong FY26 EPS

NewsDesk - July 24, 2026 8:02 am

American Express ($AXP) Beats EPS Estimates; Revenue Misses Amid Strong YoY Growth

Catalyst Desk - July 24, 2026 8:00 am

American Express ($AXP) Beats EPS Estimates; Revenue Misses Amid Strong YoY Growth

Catalyst Desk - July 24, 2026 8:00 am

FDA Approves MannKind’s ($MNKD) Furoscix ReadyFlow for Heart Failure and CKD

NewsDesk - July 24, 2026 7:25 am

Inhibikase ($IKT) Receives FDA Orphan Drug Designation for IKT-001

Catalyst Desk - July 23, 2026 8:23 am

Tesla ($TSLA) Q2 Earnings Miss Expectations; Revenue Surges YoY

Staff Writer - July 22, 2026 5:36 pm

IBM ($IBM) Exceeds Q2 EPS and Revenue Estimates; Software Revenue Up

NewsDesk - July 22, 2026 5:13 pm

What’s behind the move in Progress Software Corporation ($PRGS) stock?

Constellation Brands, Inc. ($STZ) shares Climbing in extended trading

Why NIKE ($NKE) shares are dropping post-market?

Bob’s Discount Furniture, Inc. ($BOBS) shares tumbling 6.8% in extended trading after Mixed Q4...

CATALYST News

Outlook Therapeutics ($OTLK) Secures FDA Approval for LYTENAVA™

Charter Communications ($CHTR) Beats Q2 EPS Estimates; Revenue Decline Driven by Lower Video Revenue

SLB ($SLB) Q2 performance beats expectations; EBITDA and cash flow robust

Sensient Technologies ($SXT) Beats Q2 EPS and Revenue Estimates; Projects Strong FY26 EPS

American Express ($AXP) Beats EPS Estimates; Revenue Misses Amid Strong YoY Growth

American Express ($AXP) Beats EPS Estimates; Revenue Misses Amid Strong YoY Growth

FDA Approves MannKind’s ($MNKD) Furoscix ReadyFlow for Heart Failure and CKD

Inhibikase ($IKT) Receives FDA Orphan Drug Designation for IKT-001

Tesla ($TSLA) Q2 Earnings Miss Expectations; Revenue Surges YoY

IBM ($IBM) Exceeds Q2 EPS and Revenue Estimates; Software Revenue Up